Equity Overview
Price & Market Data
Price: $1.53
Daily Change: -$0.04 / 2.61%
Daily Range: $1.47 - $1.58
Market Cap: $94,050,000
Daily Volume: 232,180
Performance Metrics
1 Week: 5.56%
1 Month: 26.67%
3 Months: 24.59%
6 Months: -11.11%
1 Year: -58.24%
YTD: -39.20%
Company Details
Employees: 30
Sector: Health technology
Industry: Biotechnology
Country:
Details
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.